[Federal Register Volume 82, Number 80 (Thursday, April 27, 2017)]
[Notices]
[Pages 19376-19377]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08490]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-17-1074]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) has submitted 
the following information collection request to the Office of 
Management and Budget (OMB) for review and approval in accordance with 
the Paperwork Reduction Act of 1995. The notice for the proposed 
information collection is published to obtain comments from the public 
and affected agencies.
    Written comments and suggestions from the public and affected 
agencies concerning the proposed collection of information are 
encouraged. Your comments should address any of the following: (a) 
Evaluate whether the proposed collection of information is necessary 
for the proper performance of the functions of the agency, including 
whether the information will have practical utility; (b) Evaluate the 
accuracy of the agency's estimate of the burden of the proposed 
collection of information, including the validity of the methodology 
and assumptions used; (c) Enhance the quality, utility, and clarity of 
the information to be collected; (d) Minimize the burden of the 
collection of information on those who are to respond, including 
through the use of appropriate automated, electronic, mechanical, or 
other technological collection techniques or other forms of information 
technology, e.g., permitting electronic submission of responses; and 
(e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570 or send an email to [email protected]. Written comments and/or 
suggestions regarding the items contained in this notice should be 
directed to the Attention: CDC Desk Officer, Office of Management and 
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written 
comments should be received within 30 days of this notice.

Proposed Project

    Colorectal Cancer Control Program (CRCCP) Monitoring Activities 
(OMB Control Number 0920-1074, expires 06/30/2019)--Revision--National 
Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), 
Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    CDC is requesting a revision to the approved information collection 
under OMB Control Number 0920-1074. CDC proposes use of a revised 
grantee survey instrument, as well as a revised clinic-level data 
collection template. The number of respondents will also decrease from 
31 to 30 grantees, and the total estimated annualized burden will 
decrease.
    Colorectal cancer (CRC) is the second leading cause of death from 
cancer in the United States among cancers that affect both men and 
women. CRC screening has been shown to reduce incidence of and death 
from the disease. Screening for CRC can detect disease early when 
treatment is more effective and prevent cancer by finding and removing 
precancerous polyps. Of individuals diagnosed with early stage CRC, 
more than 90% live five or more years. To reduce CRC morbidity, 
mortality, and associated costs, use of CRC screening tests must be 
increased among age-eligible adults with the lowest CRC screening 
rates.
    The purpose of the Colorectal Cancer Control Program (CRCCP): 
Organized Approaches to Increase Colorectal Cancer Screening (CDC-RFA-
DP15-1502), is to increase CRC screening rates among an applicant 
defined target population of persons 50-75 years of age within a 
partner health system serving a defined geographical area or disparate 
population. The CRCCP includes 30 grantees that are state governments 
or bona-fide agents, universities, and tribal organizations.
    The CRCCP was significantly redesigned in 2015 and has two 
components. Under Component 1, all grantees receive funding to support 
partnerships with health systems to implement up to four priority 
evidence-based interventions (EBIs) described in the Guide to Community 
Preventive Services, as well as other supporting activities (SAs). 
Grantees must implement at least two EBIs in each partnering health 
system. Under Component 2, six of the 30 grantees provide direct 
screening and follow-up clinical services for a limited number of 
individuals aged 50-64 in the program's priority population who are 
asymptomatic, at average risk for CRC, have inadequate or no health 
insurance for CRC screening, and are low income.
    Two forms of data collection have been implemented to assess 
program processes and outcomes. In Program Year 1, the annual grantee 
survey monitored grantee program implementation, including (1) program 
management, (2) implementation of the EBIs and SAs, (3) health 
information technology (IT), (4) partnerships, (5) data use, (6) 
training and technical assistance (TA), and (7) clinical service 
delivery (for programs receiving

[[Page 19377]]

Component 2 funding only). Clinic-level data collection assessed 
CRCCP's primary outcome of interest--CRC screening rates within partner 
health systems--by measuring: (1) Partner health system, clinic, and 
patient population characteristics, (2) reporting period (for screening 
rates), (3) Chart review screening rate data, (4) Electronic Health 
Record (EHR) screening rate, and (5) Priority evidence-based EBIs and 
SAs.
    Based on feedback from grantees and internal subject matter 
experts, CDC proposes use of updated data collection instruments. 
Specifically, CDC plans to implement a revised CRCCP grantee survey 
that eliminates questions related to EBI and SA implementation as these 
data are more accurately reported at the clinic level. Conversely, CDC 
will implement a revised CRCCP clinic-level data collection template 
with additional data variables related to EBI and SA implementation, as 
well as monitoring and evaluation activities, at the clinic level.
    Redesigned data elements will enable CDC to better gauge progress 
in meeting CRCCP program goals and monitor implementation activities, 
evaluate outcomes, and identify grantee technical assistance needs. In 
addition, data collected will inform program improvement and help 
identify successful activities that need to be maintained, replicated, 
or expanded.
    OMB approval is requested for three years. The total estimated 
annualized burden hours have decreased from 210 to 204 hours. There are 
no costs to respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                     Number of    Average burden
          Type of respondent                    Form name            Number of     responses per   per response
                                                                    respondents     respondent       (in hrs)
----------------------------------------------------------------------------------------------------------------
CRCCP Grantees........................  CRCCP Annual Grantee                  30               1           24/60
                                         Survey.
                                        CRCCP Clinic-level                    30              12           32/60
                                         Information Collection
                                         Template.
                                                                 -----------------------------------------------
    Total.............................
----------------------------------------------------------------------------------------------------------------


Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-08490 Filed 4-26-17; 8:45 am]
 BILLING CODE 4163-18-P